Objectives: The LOXL1 (lysyl oxidase-like 1) gene encodes a copperdependent monoamine oxidase that catalyzes the deamination of a lysine residue in the cross-linking of tropoelastin monomers to form elastin. LOXL1-KO mice do not deposit normal elastic fibers in their genitourinary tract resulting in postpartum pelvic organ prolapse and lower urinary tract dysfunction with decreased bladder capacity and lower voiding pressure. We sought to identify which single nucleotide polymorphisms in the LOXL1 coding sequence play a role in female pelvic organ prolapse.
F emale pelvic floor dysfunction leading to urinary incontinence, anal incontinence, pelvic organ prolapse, and sexual and lower genitourinary dysfunction affects more than one third of adult women in the United States. 1 Ultimately, the lifetime risk for women to undergo surgery for prolapse or incontinence is reported to be between 11% and 19%. 2, 3 Costs and quality of life concerns are significant within the context of an aging society, where surgical repair of prolapse is the most common inpatient procedure performed in women older than 70 years. 4Y6 Female pelvic organ prolapse (FPOP) is defined as the abnormal descent or herniation of the pelvic organs protruding against the vaginal wall. The organs involved may include the uterus, vaginal apex, anterior vagina, or posterior vagina. 7 Although the pathophysiology of FPOP is not yet well defined, it is believed to be multifactorial, with genetically predisposed women developing prolapse after certain life events. 8 The major risk factors for FPOP are increasing parity, aging, estrogen deficiency, obesity, smoking, and collagen and elastin deficienciesV particularly in patients with connective tissue disorders such as Marfan or Ehlers-Danlos syndrome. 1, 9, 10 Anatomically, the pelvic floor holding the pelvic organs in place includes the endopelvic fascia, the levator muscles, and the perineal body in addition to the bony pelvis. The tensile strength provided by the connective tissues of these organs responds to abdominal pressures to prevent FPOP pathophysiology. These tissues are particularly rich in elastin in addition to collagen. 11 Elastin has an important role in providing resiliency and strength to the pelvic floor. A rat model has displayed elastin's high turnover and its important role in remodeling the pelvis during pregnancy and childbirth. 12 Elastin attains its tensile strength and resiliency by forming a cross-linked polymer. The LOXL1 (lysyl oxidase-like 1) gene, located at 15q24.1, encodes a copper-dependent monoamine oxidase that catalyzes the deamination of a lysine residue on tropoelastin monomers in the formation of cross-links between monomers to generate elastin polymers. 13 LOXL1-KO mice do not deposit normal elastic fibers in their genitourinary tract and show gross postpartum pelvic organ prolapse and lower urinary tract dysfunction with lower bladder capacity and voiding pressure. 14 This finding of a mouse model for FPOP has sparked interest in the possible role of LOXL1 in the pathophysiology of FPOP.
The above studies emphasize the importance of further study of LOXL1 as a potential candidate in a genetic or epigenetic etiology of FPOP. Most of the published studies investigating LOXL1 involvement in FPOP have produced seemingly contradictory results. Three studies found reduced LOXL1 expression in premenopausal, postmenopausal, or a mixed population of women with pelvic organ prolapse, suggesting a mechanism of suboptimal elastin polymerization leading to FPOP. 15Y17 The group subsequently found increased cytosine-phosphate-guanine methylation in the LOXL1 gene promoter in DNA from a mixed population of women with FPOP and lower LOXL1 mRNA levels suggesting a possible epigenetic mechanism. 18 Conversely, Jung et al 19 found increased expression of LOXL1 mRNA in postmenopausal women with FPOP, which they proposed was due to compensatory induction of LOXL1 expression secondary to aberrant cross-linking of tropoelastin. Nevertheless, these studies support the idea that some forms of dysfunctional LOXL1 expression or activity remain potential etiologies for FPOP.
A previous genetic study identified a single nucleotide polymorphism (SNP) in the promoter region of the LOXL1 gene and showed that the minor allele yielded higher expression than the major allele in promoter-reporter assays in cultured cells. 20 However, they found no differences in frequencies of the promoter allelic pairs in FPOP patients compared with controls. To explore genetic factors that might impact LOXL1 activity or expression, we investigated the genotypes of the LOXL1 coding sequence in women with stage III/IV FPOP and nonasymptomatic women. Therefore the goal of this study was to determine if women with and without FPOP demonstrate significant differences in LOXL1 exon SNPs.
MATERIALS AND METHODS

Study Population
This study conformed to the tenets of the Declaration of Helsinki and was approved by the internal review boards (IRB 06-093) of the Cleveland Clinic Foundation. All blood samples were obtained after informed consent was secured.
The cases were composed of women over the age of 18 with stage III or IV FPOP and without any other type of pelvic floor dysfunction including stress urinary incontinence (SUI) or urge urinary incontinence. The control group was composed of women older than 18 years without any pelvic floor dysfunction who were being seen for a benign vaginal surgical intervention.
Patients were excluded if they had a physical or mental disability that precluded them from informed consent. Patients were also excluded if their conditions were diagnosed with 1 or more reproductive malignancies. An earlier study identified a sequence variant of the LAMC1 gene, rs10911193, as associated with familial FPOP. LAMC1 is an extracellular matrix glycoprotein that is highly expressed in smooth muscle. 21, 22 To rule out the familial LAMC1 genetic factor for FPOP, we screened our patients for this SNP and excluded them if they had the FPOP-associated variant. All patients were freely able to discontinue participation in the study at any time.
Mutation Screening
A 10-mL blood sample was collected from each patient. For mutation detection, polymerase chain reaction (PCR) products corresponding to the LOXL1 coding sequence (GenBank RefSeq NM_005576.2) were amplified from genomic DNA and analyzed by direct genomic sequencing. The 7 coding exons and immediately flanking intron sequences of LOXL1 were amplified using the 9 sense and antisense primer pairs shown in Table 1 . Three primer pairs were designed for exon 1 to yield smaller overlapping amplicons. The buffer pH, Mg 2+ concentration, annealing temperature, and presence or absence of 10% dimethyl sulfoxide were tailored to each primer pair to yield optimal amplification. ExoSAP reagent (Affymetrix, Santa Clara, Calif ) was used to remove unincorporated primers and dNTPs, and a Performa V3 Well Plate Kit (EdgeBio, Gaithersburg, Md) was used to remove gel-loading dye. Direct sequencing was performed using a Big Dye Terminator v1.1 Cycle Sequencing Kit (Applied Biosystems, Grand Island, NY) according to the manufacturer's protocol, and sequences were resolved on a CEQ-2000 automated sequencer (Beckman Coulter Inc, Indianapolis, Ind). Collected data were analyzed with SeqScape v2.5 software (Applied Biosystems).
Statistics
Genotype frequencies were tested for deviation from Hardy-Weinberg equilibrium by Pearson W 2 test. Allele frequencies were compared in case versus control groups by Fisher exact test, along with calculations of odds ratios (ORs) and 95% confidence intervals (CIs), using Graphpad Prism 6. Post hoc power analyses of the missense polymorphisms were conducted using Graphpad Statmate 2 and Prism 6 to determine the following: (a) the 
RESULTS
Sequence Changes in LOXL1
A total of 66 patients were screened for LOXL1 SNPs, 48 in the case group and 18 in the control group. The case group's mean age was 65.4 years with an SD of 9.1 years. The control group's mean age was 56.9 with an SD of 9.0 years. Both case and control groups had similar body mass index (BMI) means of 26.8 and 26.6, respectively. Most patients were white, 45 of 48 in the case group and 14 of 18 in the control group. The mean parity of cases was 1.4 with an SD of 1.5, whereas the mean parity of the controls was 1.0 with an SD of 1.4 ( Table 2) .
Three missense sequence changes (Arg141Leu-rs1048661, Gly153Asp-rs3825942, and Ser159Ala-rs78803776) and 2 silent SNPs (Asp292Asp-rs41429348 and Ala320Ala-rs41435250) were identified in LOXL1 exon 1, and 1 silent SNP (Ile521Ile-rs369758147) was found in exon 5 (Fig. 1 ). None of those polymorphisms were found to differ significantly in frequency in the case group compared with the control group in comparisons of overall allele frequencies or of the diploid genotypes. All of the SNP frequencies in both the patient and control groups were in Hardy-Weinberg equilibrium. Post hoc power analyses of the allele frequencies of the 3 missense polymorphisms revealed that the study had low power to detect the minor differences observed between FPOP patients and controls as significant, but it had about 80% power to detect differences of about 2-fold in the more common SNPs (Arg141Leu and Gly153Asp) (minimal detectable difference in Table 3 ).
The Gly153Asp and Ser159Ala sequence changes were predicted to be ''tolerated changes based on homologues in protein alignment'' by SIFT algorithm and ''benign changes with sensitivities greater than 0.9 by the PolyPhen-2 algorithm.'' The Arg141Leu sequence change resulted in the SIFT algorithm predicting a ''damaging'' change based on homologues in protein alignment and a ''possibly damaging'' change by the PolyPhen-2 algorithm.
The Arg141Leu and Gly153Asp polymorphisms were by far the most common of the 6 SNPs found in our study population; the CTG (Leu141) allele was detected in 30.2% and 30.6% of the patients and controls, respectively, and the GAC (Asp153) allele was detected in 20.8% and 16.7% of the patients and controls, respectively ( Table 3 ). Those allelic frequencies are similar to what others have found in control groups of other LOXL1 SNP studies. 25, 26 None of the other SNPs were found homozygously in any of the FPOP patients or control individuals. The missense SNP Ser159Ala was found heterozygously in 1 patient in the case group and 1 patient in the control group. The silent polymorphisms Asp292Asp, Ala320Ala, and Ile521Ile were each found heterozygously in 1 control individual; Asp292Asp was found in 2 FPOP patients, whereas none of the FPOP patients harbored either of the other silent SNPS.
DISCUSSION
Female pelvic organ prolapse is a common and costly condition with severe reductions in the quality of women's lives. The exact pathophysiology of FPOP remains to be determined. Herein, we sought evidence for a genetic predisposition to developing FPOP. Although fairly stable in other tissues, elastin has a high turnover rate in the pelvis as a result of its significant role in remodeling during pregnancy and childbirth. 12 There is evidence that LOXL1 localizes specifically to the sites of elastogenesis. 13 The potential that LOXL1 mutations may play a role in human FPOP has been displayed by LOXL1-KO mice, which model the many symptoms of FPOP in humans. 14 This is the first study to analyze the human LOXL1 coding sequence for SNPs in FPOP patients in comparison with asymptomatic women. Of the 6 sequence variations identified in LOXL1, none were found to differ significantly in frequency between the case and control groups. Our findings, therefore, suggest that the basis of FPOP in our patients is not associated with polymorphisms in the LOXL1 coding sequence. The authors acknowledge the possibility that the size of our study population was not large enough to detect a significant difference between FPOP patients and controls †Difference between the percentages of cases and controls that could be detected as significant (P G 0.05 by 2-tailed Fisher exact test) with 80% power and the given group sizes.
‡Fold increase in sample size (maintaining the same ratio of cases to controls) necessary for the observed difference to be considered significant (P G 0.05 by 2-tailed Fisher exact test).
HWE, Hardy-Weinberg equilibrium; SIFT, SIFT algorithm. if LOXL1 SNPs contribute to a small proportion of FPOP cases. However, if any of the SNPs played a major role in most FPOP cases, it is likely that the difference between groups would have been large enough to be detected as significant in this study (Table 3) . Another potential limitation of the study is that the mean age of the controls was 8.5 years less than the cases, and therefore, control patients may develop prolapse at a later age. In addition, we do not report our patients' menopausal status although most of our patients' ages would suggest that they are postmenopausal. Although menopause does not affect the distribution and frequencies of SNPs, it is possible that menopause and estrogen status could impact prolapse. The mutation Ser159Ala, found heterozygously in 1 case patient and in 1 control patient, is currently listed as a single nucleotide variation of unknown clinical significance and merits further study. The silent mutations Asp292Asp, Ala320Ala, and Ile521Ile would also benefit from a larger study to note if their associations would have any clinical implications.
LOXL1's roles in several pathologies have been investigated by SNP analyses. Of particular interest to the current study, a possible association of the homozygous CTG (Leu141) polymorphism with SUI was reported in a study of Turkish women. 27 Stress urinary incontinence and FPOP often present concurrently due to reasons such as urethral hypermobility and similar risk factors. 28, 29 We believe it to be likely that SUI, FPOP, and LOXL1 are interconnected and that LOXL1 may be 1 of the links and that it warrants further study in the future. Missense and silent SNPs have also been found in LOXL1 exons in the study of glaucoma. Two missense SNPs in exon 1 have been associated with pseudoexfoliation syndrome. Specifically, the strongly linked CGG (Arg141) and GGC (Gly153) alleles, which predominate over the respective CTG (Leu141) and GAC (Asp153) alleles in most populations, have been associated with an increased risk of pseudoexfoliation syndrome. 30 The different associations of rs1048661 (Arg141Leu) alleles with pseudoexfoliation syndrome/glaucoma and SUI suggest a pleiotropic and complex function of LOXL1 in cross-linking elastin and emphasize the importance of investigating its role in FPOP. 27, 30 These associations also provide justification for the SIFT and PolyPhen-2 results predicting disease-causing amino acid substitutions based on sequence and structural changes. Similar to our results, other studies of LOXL1 SNPs found no significant association with Alzheimer disease 31 or adolescent idiopathic scoliosis 32 despite suggestive evidence from studies of animal models. 33,34 LOXL1's cross-linking elastin has been suggested to be a mechanism for vessel stability and therefore protective during development of vascular disease such as abdominal aortic aneurysm. 35 Other pathologies implicated in human studies include deregulation of LOXL1 in endometriosis and spontaneous cervical artery dissection. 36, 37 These various pathologies are based on the evidence that LOXL1 has a role in breakdown and resynthesis of elastic fibers and connective tissue. If LOXL1 is unable to rebuild properly after damage by factors such as pregnancy, parturition, and aging, this may lead to prolapse and hypermobility of pelvic organs and other pathologies from damage to respective organ systems. 11 Although our study did not demonstrate SNPs of LOXL1 to be associated with FPOP, we do believe there is ample evidence for a role of LOXL1 in the pathophysiology of FPOP. Further research of different patient cohorts with larger sample numbers is warranted.
CONCLUSIONS
In this study, we did not find the frequency of LOXL1 polymorphisms to be significantly different in the FPOP patients compared with the control subjects. However, much evidence points to the development of FPOP from elastin and the expressed protein LOXL1 dysfunction, and our results do not exclude this etiology. Extracellular matrix and connective tissue protein expression can be modulated by forces such as BMI, bony pelvic anatomy, pelvic trauma, pelvic injury, and pelvic stressors such as cough, exercise, and pregnancy. Therefore, these factors remain important to study. Future studies should investigate these mechanisms influencing LOXL1 expression with particular regard to epigenetic control, as well as posttranscriptional and posttranslational processes. Those processes may determine elastin content through an effect on LOXL1 and therefore may influence predisposition for FPOP.
